Home › XELJANZ (Tofacitinib Citrate) Approved In Japan For The Treatment Of Adults With Rheumatoid Arthritis (RA)
 

Keywords :   


XELJANZ (Tofacitinib Citrate) Approved In Japan For The Treatment Of Adults With Rheumatoid Arthritis (RA)

2013-03-25 08:00:00| drugdiscoveryonline News Articles

Pfizer Inc. announced recently that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies

Tags: with japan treatment approved

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Horizon expert 'gave evidence based on informal chats'
26.06Automotive Color by BASF Recognized with Renowned Red Dot Award
26.06Beckers Commits to Widespread Science Based Targets
26.06PPG to Announce Second-quarter 2024 Results July 18
26.06Fresh Coat for First Responders: New Hampshire Fire Station Gets a Makeover by California Paints
26.06Michigan Sets Record Recycling Rate in 2023, Recycles Nearly 70,000 Tons of Materials
26.06Companies Seek Federal EPR: How Producers Can Prepare
26.06Q&A with GFLs Tyler Stefure: Integrating New Fleet Tech & Upholding GFL Values
More »